Do analysts recommend ONCO or ADIL?

Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 500.44%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Do analysts recommend ONCO or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ONCO or PULM?

Pulmatrix has higher revenue and earnings than Onconetix. Pulmatrix is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Onconetix $810K 1.54 -$14.03M $11.40 0.10 Pulmatrix $7.81M 0.66 -$5.16M -$1.23 N/A

Is ONCO or PULM more profitable?

Pulmatrix has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Onconetix -1,316.28% -101.08% -47.34% Pulmatrix N/A -107.84% -91.58%

Do analysts recommend ALBT or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend DCOY or ONCO?

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PBM or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Onconetix (ONCO) Competitors

$1.10 +0.08 (+7.35%)

As of 01:38 PM Eastern

Compare

ONCO vs. ADIL, PULM, ALBT, DCOY, and PBM

Should you buy Onconetix stock or one of its competitors? MarketBeat compares Onconetix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Onconetix include Adial Pharmaceuticals (ADIL), Pulmatrix (PULM), Avalon GloboCare (ALBT), Decoy Therapeutics (DCOY), and Psyence Biomedical (PBM). These companies are all part of the "pharmaceutical products" industry.

How does Onconetix compare to Adial Pharmaceuticals?

Onconetix (NASDAQ:ONCO) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 1.9% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Adial Pharmaceuticals has lower revenue, but higher earnings than Onconetix. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	1.54	-$14.03M	$11.40	0.10
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A

In the previous week, Adial Pharmaceuticals had 6 more articles in the media than Onconetix. MarketBeat recorded 7 mentions for Adial Pharmaceuticals and 1 mentions for Onconetix. Onconetix's average media sentiment score of 1.87 beat Adial Pharmaceuticals' score of 0.45 indicating that Onconetix is being referred to more favorably in the media.

Company	Overall Sentiment
Onconetix	Very Positive
Adial Pharmaceuticals	Neutral

Onconetix has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

Adial Pharmaceuticals has a consensus price target of $17.17, suggesting a potential upside of 500.44%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Adial Pharmaceuticals is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Adial Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Adial Pharmaceuticals	N/A	-162.82%	-127.58%

Summary

Onconetix beats Adial Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to Pulmatrix?

Onconetix (NASDAQ:ONCO) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Onconetix and Onconetix both had 1 articles in the media. Pulmatrix's average media sentiment score of 1.89 beat Onconetix's score of 1.87 indicating that Pulmatrix is being referred to more favorably in the news media.

Company	Overall Sentiment
Onconetix	Very Positive
Pulmatrix	Very Positive

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pulmatrix has higher revenue and earnings than Onconetix. Pulmatrix is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	1.54	-$14.03M	$11.40	0.10
Pulmatrix	$7.81M	0.66	-$5.16M	-$1.23	N/A

Pulmatrix has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,316.28%	-101.08%	-47.34%
Pulmatrix	N/A	-107.84%	-91.58%

Onconetix has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Onconetix beats Pulmatrix on 7 of the 12 factors compared between the two stocks.

How does Onconetix compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Avalon GloboCare and Avalon GloboCare both had 1 articles in the media. Avalon GloboCare's average media sentiment score of 1.87 equaled Onconetix'saverage media sentiment score.

Company	Overall Sentiment
Avalon GloboCare	Very Positive
Onconetix	Very Positive

Onconetix has higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	N/A	N/A	-$18.26M	-$3.51	N/A
Onconetix	$810K	1.54	-$14.03M	$11.40	0.10

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avalon GloboCare has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Avalon GloboCare's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Onconetix	-1,316.28%	-101.08%	-47.34%

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 24.2% of Avalon GloboCare shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalon GloboCare has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.73, indicating that its stock price is 173% more volatile than the broader market.

Summary

Onconetix beats Avalon GloboCare on 7 of the 10 factors compared between the two stocks.

How does Onconetix compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Onconetix (NASDAQ:ONCO) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Decoy Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market.

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 1.7% of Decoy Therapeutics shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Decoy Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Onconetix's return on equity of -101.08% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Onconetix	-1,316.28%	-101.08%	-47.34%

Decoy Therapeutics has higher earnings, but lower revenue than Onconetix. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Onconetix	$810K	1.54	-$14.03M	$11.40	0.10

Decoy Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 385.04%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Decoy Therapeutics had 3 more articles in the media than Onconetix. MarketBeat recorded 4 mentions for Decoy Therapeutics and 1 mentions for Onconetix. Onconetix's average media sentiment score of 1.87 beat Decoy Therapeutics' score of 0.37 indicating that Onconetix is being referred to more favorably in the news media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Onconetix	Very Positive

Summary

Onconetix beats Decoy Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to Psyence Biomedical?

Psyence Biomedical (NASDAQ:PBM) and Onconetix (NASDAQ:ONCO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Psyence Biomedical has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Onconetix has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical has higher earnings, but lower revenue than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.13
Onconetix	$810K	1.54	-$14.03M	$11.40	0.10

In the previous week, Psyence Biomedical had 1 more articles in the media than Onconetix. MarketBeat recorded 2 mentions for Psyence Biomedical and 1 mentions for Onconetix. Onconetix's average media sentiment score of 1.87 beat Psyence Biomedical's score of 1.43 indicating that Onconetix is being referred to more favorably in the news media.

Company	Overall Sentiment
Psyence Biomedical	Positive
Onconetix	Very Positive

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Psyence Biomedical has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Psyence Biomedical's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Onconetix	-1,316.28%	-101.08%	-47.34%

Summary

Psyence Biomedical beats Onconetix on 9 of the 12 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.25M	$3.40B	$6.50B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	0.10	20.08	23.99	24.69
Price / Sales	1.54	322.83	538.03	166.93
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.00	8.06	10.47	6.82
Net Income	-$14.03M	$23.89M	$3.56B	$337.45M
7 Day Performance	8.42%	2.75%	1.21%	2.49%
1 Month Performance	-70.72%	0.70%	2.14%	4.37%
1 Year Performance	-99.54%	45.69%	26.24%	32.80%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	2.3664 of 5 stars	$1.10 +7.4%	N/A	-99.6%	$1.25M	$810K	0.10	12	Positive News Gap Up
ADIL Adial Pharmaceuticals	3.6094 of 5 stars	$2.27 -3.8%	$22.75 +902.2%	-66.0%	$4.86M	N/A	N/A	20	Analyst Downgrade Gap Up
PULM Pulmatrix	1.2186 of 5 stars	$1.32 flat	N/A	-82.1%	$4.82M	$7.81M	N/A	20	Positive News
ALBT Avalon GloboCare	1.0556 of 5 stars	$0.39 +4.6%	N/A	-89.5%	$4.65M	N/A	N/A	5
DCOY Decoy Therapeutics	2.1102 of 5 stars	$8.22 -4.5%	$30.00 +265.0%	N/A	$4.37M	N/A	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. ADIL, PULM, ALBT, DCOY, and PBM

How does Onconetix compare to Adial Pharmaceuticals?

Summary

How does Onconetix compare to Pulmatrix?

Summary

How does Onconetix compare to Avalon GloboCare?

Summary

How does Onconetix compare to Decoy Therapeutics?

Summary

How does Onconetix compare to Psyence Biomedical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. ADIL, PULM, ALBT, DCOY, and PBM

How does Onconetix compare to Adial Pharmaceuticals?

Do insiders & institutionals hold more shares of ONCO or ADIL?

Which has preferable earnings and valuation, ONCO or ADIL?

Does the media prefer ONCO or ADIL?

Which has more risk & volatility, ONCO or ADIL?

Do analysts recommend ONCO or ADIL?

Is ONCO or ADIL more profitable?

Summary

How does Onconetix compare to Pulmatrix?

Does the media prefer ONCO or PULM?

Do insiders and institutionals hold more shares of ONCO or PULM?

Which has stronger valuation and earnings, ONCO or PULM?

Is ONCO or PULM more profitable?

Which has more risk and volatility, ONCO or PULM?

Do analysts recommend ONCO or PULM?

Summary

How does Onconetix compare to Avalon GloboCare?

Does the media refer more to ALBT or ONCO?

Which has higher valuation and earnings, ALBT or ONCO?

Do analysts recommend ALBT or ONCO?

Is ALBT or ONCO more profitable?

Do insiders and institutionals have more ownership in ALBT or ONCO?

Which has more risk and volatility, ALBT or ONCO?

Summary

How does Onconetix compare to Decoy Therapeutics?

Which has more risk & volatility, DCOY or ONCO?

Do insiders & institutionals believe in DCOY or ONCO?

Is DCOY or ONCO more profitable?

Which has higher valuation and earnings, DCOY or ONCO?

Do analysts recommend DCOY or ONCO?

Does the media favor DCOY or ONCO?

Summary

How does Onconetix compare to Psyence Biomedical?

Which has more risk & volatility, PBM or ONCO?

Do analysts recommend PBM or ONCO?

Which has higher earnings and valuation, PBM or ONCO?

Does the media favor PBM or ONCO?

Do institutionals and insiders hold more shares of PBM or ONCO?

Is PBM or ONCO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools